ENOblock inhibits the pathology of diet-induced obesity

Area of Science:

• Biochemistry
• Metabolic Diseases
• Pharmacology

Background:

• Obesity is a complex global health issue linked to severe comorbidities like diabetes and cardiovascular disease.
• Enolase, a glycolysis enzyme, possesses secondary functions ('moonlighting') that influence cellular processes relevant to obesity.
• Identifying novel therapeutic targets for obesity remains a critical unmet medical need.

Purpose of the Study:

• To investigate the therapeutic potential of targeting enolase's moonlighting functions for obesity treatment.
• To evaluate the efficacy of ENOblock, a novel enolase modulator, in preclinical models of obesity.

Main Methods:

• Adipocytes were treated with ENOblock to assess its effects on adipogenesis and mitochondrial function.
• Obese animal models were administered ENOblock to evaluate its impact on body weight, core body temperature, and metabolic parameters.
• Molecular mechanisms were elucidated by analyzing gene expression related to lipid homeostasis, gluconeogenesis, and inflammation.

Main Results:

• ENOblock treatment suppressed adipocyte differentiation and induced mitochondrial uncoupling.
• Obese animals exhibited reduced body weight, increased core body temperature, and improved metabolic and inflammatory markers in key tissues.
• ENOblock demonstrated a mechanism involving transcriptional repression of key regulators of lipid metabolism, gluconeogenesis, and inflammation.
• In high-fat diet-fed mice, ENOblock reduced weight gain, food intake, and increased fecal lipid excretion.

Conclusions:

• Enolase represents a promising new therapeutic target for obesity.
• ENOblock shows significant potential as a drug candidate for obesity treatment, warranting further development.